Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970407 | 0.90 | SIGMAR1 (0.53) | SIGMAR1HTR1ADRD2CHRM2CHRM1 | |
| SCHEMBL8970411 | 0.86 | SIGMAR1 (0.58) | SIGMAR1HTR1ADRD2CHRM2CHRM1 | |
| SCHEMBL9238577 | 0.81 | MTNR1A (0.48) | SIGMAR1HTR1ACHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL9237392 | 0.80 | MTNR1A (0.47) | SIGMAR1HTR1ACHRM2CHRM1CHRM3 | |
| SCHEMBL8074250 | 0.76 | DRD2 (0.83) | DRD2MTNR1AMTNR1B | |
| SCHEMBL7543711 | 0.76 | DRD2 (0.83) | DRD2MTNR1AMTNR1B | |
| SCHEMBL8074280 | 0.76 | DRD2 (0.83) | DRD2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL8604442 | 0.75 | DRD2 (0.81) | DRD2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7932989 | 0.75 | DRD2 (0.81) | DRD2MTNR1AMTNR1B | |
| SCHEMBL8970384 | 0.75 | CHRM2 (0.60) | SIGMAR1HTR1ADRD2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ADRA2B, ADRA1B, ADRB2 | SIGMAR1 266/4885HTR1A 17/4885DRD2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.